Gastrointestinal stromal tumor - An overview

被引:1
作者
Ramaswamy, Anant [1 ]
Chaudhari, Vikram [2 ]
Bhargava, Prabhat [1 ]
Bhandare, Manish [2 ]
Kumar, Rajiv [3 ]
Shrikhande, Shailesh, V [2 ]
Ostwal, Vikas [1 ]
机构
[1] Tata Mem Hosp, Homi Bhabha Natl Inst HBNI, Dept Med Oncol, Mumbai, Maharashtra, India
[2] Tata Mem Hosp, Homi Bhabha Natl Inst, Dept Surg Oncol, GI & HPB Surg, Mumbai, Maharashtra, India
[3] Tata Mem Hosp, Homi Bhabha Natl Inst, Dept Pathol, Mumbai, Maharashtra, India
关键词
Gastrointestinal stromal tumor; Indian data; overview; IMATINIB MESYLATE; C-KIT; NEOADJUVANT IMATINIB; RISK STRATIFICATION; RESPONSE EVALUATION; ADJUVANT IMATINIB; PHASE-III; PDGFRA MUTATIONS; DOSE IMATINIB; GIST;
D O I
10.4103/ijmpo.ijmpo_45_20
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastrointestinal stromal tumors (GISTs) are rare tumors but are most common mesenchymal tumors of the digestive tract. They are commonly seen in the stomach (60%) and small intestine (30%). GISTs are likely derived from the interstitial cells of Cajal or their stem cell precursors. They are best characterized by computerized tomography and have a specific staining pattern on immunohistochemistry, i.e., C-Kit and DOG-1. The treatment of GIST is based on the risk assessment for relapse, and patients with localized GIST require resection with or without adjuvant imatinib mesylate (IM). Advanced unresectable tumors are usually treated with IM, with a number of further options available for patients post progression on IM. There is an increasing emphasis on identifying C-Kit and platelet-derived growth factor receptor alpha mutations in all patients with GIST, as these are driver mutations with current and future therapeutic implications.
引用
收藏
页码:809 / 818
页数:10
相关论文
共 83 条
[1]  
Babu MCS, 2017, SOUTH ASIAN J CANCER, V6, P118, DOI 10.4103/sajc.sajc_290_16
[2]   Gastrointestinal stromal tumors [J].
Beham, Alexander W. ;
Schaefer, Inga-Marie ;
Schueler, Philipp ;
Cameron, Silke ;
Ghadimi, B. Michael .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (06) :689-700
[3]   Open Versus Minimally Invasive Resection of Gastric GIST: A Multi-Institutional Analysis of Short- and Long-Term Outcomes [J].
Bischof, Danielle A. ;
Kim, Yuhree ;
Dodson, Rebecca ;
Jimenez, M. Carolina ;
Behman, Ramy ;
Cocieru, Andrei ;
Blazer, Dan G., III ;
Fisher, Sarah B. ;
Squires, Malcolm H., III ;
Kooby, David A. ;
Maithel, Shishir K. ;
Groeschl, Ryan T. ;
Gamblin, T. Clark ;
Bauer, Todd W. ;
Karanicolas, Paul J. ;
Law, Calvin ;
Quereshy, Fayez A. ;
Pawlik, Timothy M. .
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (09) :2941-2948
[4]   Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].
Blanke, Charles D. ;
Demetri, George D. ;
von Mehren, Margaret ;
Heinrich, Michael C. ;
Eisenberg, Burton ;
Fletcher, Jonathan A. ;
Corless, Christopher L. ;
Fletcher, Christopher D. M. ;
Roberts, Peter J. ;
Heinz, Daniela ;
Wehre, Elisabeth ;
Nikolova, Zariana ;
Joensuu, Heikki .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625
[5]  
Blay JY, 2007, J CLIN ONCOL, V25, P1107, DOI 10.1200/JCO.2006.09.0183
[6]  
Bose S, 2017, SOUTH ASIAN J CANCER, V6, P110, DOI 10.4103/sajc.sajc_323_16
[7]   Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study [J].
Cameron, Silke .
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 3
[8]   Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 68, 2018) [J].
Casali, P. G. ;
Abecassis, N. ;
Aro, H. T. ;
Bauer, S. ;
Biagini, R. ;
Bielack, S. ;
Bonvalot, S. ;
Boukovinas, I. ;
Bovee, J. V. M. G. ;
Brodowicz, T. ;
Broto, J. M. ;
Buonadonna, A. ;
De Alava, E. ;
Tos, A. P. Dei ;
Del Muro, X. G. ;
Dileo, P. ;
Eriksson, M. ;
Fedenko, A. ;
Ferraresi, V. ;
Ferrari, A. ;
Ferrari, S. ;
Frezza, A. M. ;
Gasperoni, S. ;
Gelderblom, H. ;
Gil, T. ;
Grignani, G. ;
Gronchi, A. ;
Haas, R. L. ;
Hassan, B. ;
Hohenberger, P. ;
Issels, R. ;
Joensuu, H. ;
Jones, R. L. ;
Judson, I. ;
Jutte, P. ;
Kaal, S. ;
Kasper, B. ;
Kopeckova, K. ;
Krakorova, D. A. ;
Le Cesne, A. ;
Lugowska, I. ;
Merimsky, O. ;
Montemurro, M. ;
Pantaleo, M. A. ;
Piana, R. ;
Picci, P. ;
Piperno-Neumann, S. ;
Pousa, A. L. ;
Reichardt, P. ;
Robinson, M. H. .
ANNALS OF ONCOLOGY, 2018, 29 :267-267
[9]   Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels [J].
Casali, Paolo G. ;
Zalcberg, John ;
Le Cesne, Axel ;
Reichardt, Peter ;
Blay, Jean-Yves ;
Lindner, Lars H. ;
Judson, Ian R. ;
Schoffski, Patrick ;
Leyvraz, Serge ;
Italiano, Antoine ;
Grunwald, Viktor ;
Pousa, Antonio Lopez ;
Kotasek, Dusan ;
Sleijfer, Stefan ;
Kerst, Jan M. ;
Rutkowski, Piotr ;
Fumagalli, Elena ;
Hogendoorn, Pancras ;
Litiere, Saskia ;
Marreaud, Sandrine ;
van der Graaf, Winette ;
Gronchi, Alessandro ;
Verweij, Jaap .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) :1713-+
[10]   Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era [J].
Cassier, Philippe A. ;
Fumagalli, Elena ;
Rutkowski, Piotr ;
Schoeffski, Patrick ;
Van Glabbeke, Martine ;
Debiec-Rychter, Maria ;
Emile, Jean-Francois ;
Duffaud, Florence ;
Martin-Broto, Javier ;
Landi, Bruno ;
Adenis, Antoine ;
Bertucci, Francois ;
Bompas, Emmanuelle ;
Bouche, Olivier ;
Leyvraz, Serge ;
Judson, Ian ;
Verweij, Jaap ;
Casali, Paolo ;
Blay, Jean-Yves ;
Hohenberger, Peter .
CLINICAL CANCER RESEARCH, 2012, 18 (16) :4458-4464